SCHEMBL10112792

SCHEMBL10112792

N#C/N=C(\N)Nc1ccc(I)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.58
KCNH2 Q12809 2/20 0.46
CYP2D6 P10635 2/20 0.46
AR P10275 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
CXCR3 P49682 1/20 0.46
IDO1 P14902 1/20 0.43
ABCC9 O60706 1/20 0.40
KCNJ11 Q14654 1/20 0.40
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
GRIN2D O15399 4/20 0.37
GRIN3B O60391 4/20 0.37
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9701789 0.83 PEPD (0.48) SIGMAR1CYP2D6CYP3A4CA12CA1
SCHEMBL1983930 0.81 NPC1 (0.50) SIGMAR1KCNH2CYP2D6ARTP53
SCHEMBL1983932 0.81 NPC1 (0.50) SIGMAR1KCNH2CYP2D6ARTP53
SCHEMBL11236640 0.81 GRIN2D (0.58) SIGMAR1CYP1A2CYP3A4CYP2C19GRIN2D
SCHEMBL11232538 0.81 GRIN2D (0.55) SIGMAR1CYP2D6TP53CYP3A4GRIN2D
SCHEMBL15094415 0.81 GRIN2D (0.55) SIGMAR1CYP2D6TP53CYP3A4GRIN2D
SCHEMBL160935 0.78 MDM2 (0.44) CYP1A2CYP3A4CYP2C19ABCC9KCNJ11
SCHEMBL5949813 0.78 SIGMAR1 (0.41) SIGMAR1KCNH2CYP2D6ARTP53
SCHEMBL5949807 0.78 SIGMAR1 (0.41) SIGMAR1KCNH2CYP2D6ARTP53
SCHEMBL15366862 0.78 MDM2 (0.44) CYP1A2CYP3A4CYP2C19ABCC9KCNJ11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 SIGMAR1 3870/4885KCNH2 4601/4885CYP2D6 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.